Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hoth Therapeutics ( (HOTH) ) has shared an update.
Hoth Therapeutics announced that it has prepared presentation materials to be used in discussions about its operations and performance starting October 17, 2025. The company is advancing its HT-001 topical gel, which addresses skin toxicity from EGFR inhibitors, and HT-KIT injection for systemic mastocytosis, with significant market growth potential. Recent milestones include positive study results for HT-001 and strategic FDA meetings for HT-KIT, indicating progress in their clinical development pipelines.
The most recent analyst rating on (HOTH) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Hoth Therapeutics stock, see the HOTH Stock Forecast page.
More about Hoth Therapeutics
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation therapeutics to address unmet patient needs. The company is involved in early-stage pharmaceutical research and development, aiming to bring promising drugs from pre-clinical to clinical testing. It collaborates with scientists, clinicians, and key opinion leaders to diversify treatment options and improve patient quality of life.
Average Trading Volume: 1,112,616
Technical Sentiment Signal: Buy
Current Market Cap: $18.96M
For an in-depth examination of HOTH stock, go to TipRanks’ Overview page.